A Pooled THC Blood-Pressure Reduction Included Species Subgroups Without Significant Changes

The THC cardiovascular review found pooled animal blood-pressure reductions while some species subgroups did not show significant changes. The pooled average did not establish a uniform response across species.

Subgroup results qualified the overall pattern

For acute dosing in anesthetized animals, the review reports significant pressure reductions in rats and cats but not in the dog subgroup. In its conscious-animal analysis, pressure comparisons in bats and rats were nonsignificant. These observations belong beside the overall pooled direction.

A subgroup null is not proof of equivalence

A nonsignificant result does not demonstrate that the true effect is exactly zero. Small samples and imprecision can matter. Conversely, a significant pooled result does not establish that each subgroup experienced the same change. Differences between significance labels also do not automatically establish a statistically significant difference between species.

The model determines how far the result travels

Dose, route, anesthesia and baseline physiology varied across the evidence. These conditions make it inappropriate to assign the pooled pressure reduction to an individual animal or human. The review supplies a conditional average across selected comparisons, with explicit exceptions and substantial heterogeneity. Preserving the subgroup results prevents a broad statement about THC lowering blood pressure from concealing what the underlying studies did and did not show.

Related analysis: the study’s broader findings and limitations.

Research cited

Sultan, Millar, O’Sullivan and England (2018). A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of Δ9-Tetrahydrocannabinol.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication

The final trial reported that efficacy results for cycles B and C were not analyzed because of substantial crossover. The first-cycle benefit therefore should not be presented as three separately demonstrated cycles of efficacy. Later treatment histories became mixed The study included different continuation and crossover arrangements across its phases….

Spread the love

Read Article: Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication

Self-Titration Produced Different Capsule Counts in Active and Placebo Chemotherapy Arms

The chemotherapy study permitted capsule adjustment according to nausea and side effects. Active and placebo participants consequently did not take the same median number of capsules per dose. Capsule content and regimen were specified Each active capsule contained 2.5 milligrams of THC and 2.5 milligrams of CBD. Treatment was scheduled…

Spread the love

Read Article: Self-Titration Produced Different Capsule Counts in Active and Placebo Chemotherapy Arms

Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views

The chemotherapy trial collected both patient-rated cannabinoid-related symptoms and clinician-graded adverse events. Their percentages should not be combined as though they used one severity definition. The assessments used different frameworks Participants completed a structured checklist including sedation, dizziness, anxiety, disorientation, hallucinations and palpitations. Clinicians used the Common Terminology Criteria for…

Spread the love

Read Article: Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us